anti-hypoxia

Moslosooflavone (5-hydroxy-7,8-dimethoxyflavone) has anti-hypoxia activity, it can significantly prolong the survival time of hypoxic mice. 5-hydroxy-7,8-dimethoxyflavone significantly inhibits the transcriptional activity of NF-kappaB in LPS/IFN-gamma stimulated RAW 264.7 macrophages.

BMY-21502 is a potential cognitive enhancer that shows anti-hypoxia effects in the KCN-hypoxia model, delays the decay of hippocampal synaptic enhancement in vitro, and can be used to study Alzheimer's disease.

Citric acid trilithium salt tetrahydrate (Lithium citrate tribasic tetrahydrate) , the active component of Lithium, is a medicine used in the therapy of psychiatric disease. It has shown the effects of signaling pathways and metabolic in the brain based on the particular disease and clinical condition model. According to the reports, Citric acid trilithium salt tetrahydrate was used as a mood stabilizer when treating bipolar mood disorders (BD) and lower the risk of self-harm in BD patient. In addition,Citric acid trilithium salt tetrahydrate has been the choice drug in the therapy of acute manic episodes.Citric acid trilithium salt tetrahydrate also could dissolve uric acid crystals in urine achieved from patients with gout. Besides,Citric acid trilithium salt tetrahydrate have some dose-dependent side-effects. The the main side-effects of Lithium Citrate is the tendency to inhibit the prostatic acid phosphatase enzyme (PAP), which result in the accumulation of PAP.

Hydroxycitric acid tripotassium hydrate (Potassium citrate monohydrate) is the major active ingredient of Garcinia cambogia and a derivative of citric acid, which effectively inhibits stone formation and HIF, and has antioxidation, anti-inflammation, and anti-tumor effects. It also competitively inhibits ATP citrate lyase, offering weight loss benefits.

HNHA is an inhibitor of HDAC.

Bellidifolin (Bellidifoline) has anti-oxidation, hepatoprotective, anti-inflammatory and antitumor actions, it may contribute to the protective effects associated with nerve injury initiated by hypoxia by mechanisms related to inhibition of cell apoptosis independent of the ERK pathway. Bellidifolin shows interesting inhibitory activity of monoamine oxidases (MAO) A, it could be useful for treating type-2 diabetes, likely via the improvement of insulin resistance (IR). Bellidifolin also shows an antifungal effect (MIC values of 50 microg/mL).

BMS-470539 dihydrochloride is a selective and highly potent melanocortin 1 receptor (MC-1 R) agonist with anti-inflammatory activity. BMS-470539 attenuates oxidative stress and neuronal apoptosis via the MC1R/cAMP/PKA/Nurr1 signaling pathway in a neonatal hypoxia-ischemia rat model.

PROTAC HIF-1α degrader-1 (compound V2) is an effective proteolysis-targeting chimeric (PROTAC) degrader of hypoxia-inducible factor-1α (HIF-1α), with an IC50 value of 7.54 µM. This compound exhibits anti-proliferative activity, reduces HIF-1α protein expression, and induces apoptosis.

Roxadustat (FG-4592) is an orally bioavailable, hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), with potential anti-anemic activity.

1. Negletein (7-O-Methylbaicalein) has anti-inflammatory and immunomodulatory activities via inhibition of TNF-α, iNOS and IL-1β. 2. Negletein as a neuroprotectant enhances the action of nerve growth factor and induces neurite outgrowth in PC12 cells. 3. Negletein shows a comparable redox-active potential, and it (50 μM, 4 h) can activate Nrf2. 4. Negletein shows significant antimicrobial activity. 5. Negletein has anti-hypoxia activity, it can significantly prolong the survival time of hypoxic mice.6. Negletein has anti- Alzheimer's disease activity, it inhibits the iron-dependent formation of ROS and also blocks the iron-induced oligomerization of amyloid beta 42 in vitro. 7. Negletein (IC50: 3.89 +/- 0.39 microM) exhibits potent inhibitory activity against nuclear factor of activated T cells (NFAT) transcription factor.

Herboxidiene (GEX1A) is a plant-toxic polyketide compound isolated from Streptomyces ATCC 49982, with herbicidal, cholesterol-lowering, and anticancer activities. It exhibits anti-angiogenic activity by downregulating vascular endothelial growth factor receptor-2 (VEGFR-2) and hypoxia-inducible factor-1α (HIF-1α).

hCAI/II-IN-4 (compound 6d) is a potent inhibitor of both hCA I and hCA II enzymes, with Ki values of 16.95 nM and 15.22 nM, respectively. It also inhibits hCA IX with a Ki value of 27.04 nM, exhibits anti-hypoxia properties, and maintains low toxicity. This compound is suitable for investigating acute mountain sickness (AMS) in research studies [1].

KCN1, a novel synthetic sulfonamide, is a HIF pathway inhibitor with potential anticancer activity in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. KCN1 specifically inhibited HIF reporter gene activity in several glioma cell lines at the nanomolar level. KCN1 also downregulated transcription of endogenous HIF-1 target genes, such as VEGF, Glut-1, and carbonic anhydrase 9, in a hypoxia-responsive element (HRE)-dependent manner. KCN1 potently inhibited the growth of subcutaneous malignant glioma tumor xenografts with minimal adverse effects on the host.

6-Methoxypurine-9-β-D-5'(R)-C-methylriboside, an analog of hypoxanthine—a purine base predominantly found in muscle tissue and a metabolite generated when purine oxidase acts on xanthine—displays anti-inflammatory properties and functions as a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. Its cytoprotective role is underscored by its ability to inhibit PARP activity, thus preventing peroxynitrite-induced mitochondrial depolarization and subsequent superoxide production. Furthermore, hypoxanthine serves as a biomarker for hypoxia [1] [2].

HYOU1-IN-1 (Compound 33), an inhibitor of hypoxia-upregulated protein 1 (HYOU1), exhibits anti-inflammatory properties. It is applicable in studies focusing on fibroblast activation, chronic inflammation, and fibrotic diseases [1].

Casdaitifan (AB521) is an orally active hypoxia inducible factor 2 alpha (HIF-2 alpha) inhibitor. Casdaitifan exhibits significant anti-tumor effects in the clear cell renal cell carcinoma (ccRCC) model.

Moslosooflavone (Standard) is a reference standard for research and analysis in studies involving Moslosooflavone. Moslosooflavone (5-hydroxy-7,8-dimethoxyflavone) has anti-hypoxia activity, it can significantly prolong the survival time of hypoxic mice. 5-hydroxy-7,8-dimethoxyflavone significantly inhibits the transcriptional activity of NF-kappaB in LPS/IFN-gamma stimulated RAW 264.7 macrophages.

Moracin O, a natural product isolated from Morus alba Linn., exhibits cytotoxicity towards 3T3-L1, RAW 264.7, and HEP 3B cells, inhibits HIF-1, and demonstrates neuroprotective and anti-inflammatory effects.

Moracin P, a 2-arylbenzofuran derivative isolated from Mori Cortex Radicis, shows potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1). This compound reduces oxygen-glucose deprivation-induced reactive oxygen species generation while demonstrating neuroprotective and anti-inflammatory properties.

N-Methylcorydalmine may exhibit significant anti-hypoxia activity.

dCNP binds to NPR-B/C receptors (NPR-B/C receptor), initiating the cGMP signaling pathway and regulating vascular function. It exhibits anti-hypoxic effects by downregulating hypoxia-related genes such as HIF1α and HIF2α. Additionally, dCNP inhibits tumor stroma induction, demonstrating antifibrotic properties. It also enhances immune response by upregulating CTL, NK cells, and conventional type 1 dendritic cells in tumors.

1. Kamebakaurin (Kamebakaurine) has the ability to protect the liver from APAP-induced hepatotoxicity, presumably by both inhibiting the inflammatory response and oxidative stress. 2. Kamebakaurin inhibits the expression of hypoxia-inducible factor-1α and its target genes to confer antitumor activity. 3. Kamebakaurin has anti-cancer and anti-inflammatory activities through direct inhibition of DNA-binding activity of nuclear factor-kappa B (NF-κB) p50.4. Kamebakaurin has anti-neuroinflammatory activity via inhibition of c-Jun NH -terminal kinase and p38 mitogen-activated protein kinase pathway in activated microglial cells.